Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial - Concepedia

Concepedia

Publication | Closed Access

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

310

Citations

24

References

2021

Year

Sibylle Loibl, Frederik Marmé, Miguel Martín, Michael Untch, Hervé Bonnefoi, Sung‐Bae Kim, Harry D. Bear, Nicole McCarthy, Mireia Melé, Karen A. Gelmon,

Journal of Clinical Oncology

Abstract

Palbociclib for 1 year in addition to ET did not improve iDFS in women with residual invasive disease after NACT.

References

	Year	Citations

Page 1